Back to results

GZ17-6.02 in Advanced Castration-Resistant Prostate Cancer (CRPC) After Progression on Anti-Androgen Therapy

Objective

Assess the efficacy of GZ17-6.02 in improving the rate of disease control, defined as radiographic progression-free survival for 6 months or more, i.e., disease control rate at 6 months (DCR6).

Protocol #

MCC-23-20417

Trial Phase:

Phase I

Principal Investigator:

Melson, John

Cancer Type
  • Prostate
Study Site
  • Stony Point
  • Virginia Commonwealth University

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Melanie Hamilton, RN
    Phone: +1 804-628-7130
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: